Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor

US5958413A · kind A · utility

Assignees

• CELLTECH CO., LTD. · GB
• Hoechst GmbH · DE

Inventors

• Hiristo Anagnostopulos · Wiesbaden, DE
• Ulrich Gebert · Königstein, DE
• Heinz Hanel · Oberursel, DE
• Michael Limbert · Hofheim, DE
• Mark Bodmer · South Hinksey, GB
• Gerald Anthony Higgs · London, GB

Key dates

• Filing date: Nov 10, 1997
• Grant date: Sep 28, 1999
• Expiry date: Nov 10, 2017

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2039/505
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A combined preparation for simultaneous combined, simultaneous separate, or sequential use in the therapy of prophylaxis of disorders associated with undesirable high levels of TNF, e.g. septic or endotoxic shock and immunoregulatory and inflammatory disorders, which comprises an antibody to TNF or a TNF binding fragment thereof and a xanthine derivative. Particular preferred xanthine derivatives are 3,7-dimethyl-1(5-oxo-hexyl)xanthine (known as Pentoxifylline or TRENTAL) and 1-(5-hydroxy-5-methylhexyl)-3-methylxanthine and similar compounds. The anti-TNF antibody or fragment is preferably monospecific especially a humanized recombinant antibody or fragment.